Evercore Begins Coverage on Avalyn Pharma (NASDAQ:AVLN)

Equities researchers at Evercore initiated coverage on shares of Avalyn Pharma (NASDAQ:AVLN) in a report issued on Tuesday. The firm set an “outperform” rating and a $51.00 price target on the stock. Evercore’s price objective points to a potential upside of 76.84% from the company’s current price.

Other analysts also recently issued reports about the company. Guggenheim initiated coverage on Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $80.00 price target for the company. Morgan Stanley began coverage on Avalyn Pharma in a research report on Tuesday. They set an “overweight” rating and a $53.00 price target for the company. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Finally, Jefferies Financial Group began coverage on Avalyn Pharma in a report on Monday. They set a “buy” rating and a $52.00 price objective for the company. Four analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $59.00.

Avalyn Pharma Price Performance

Shares of AVLN opened at $28.84 on Tuesday. Avalyn Pharma has a 12 month low of $25.05 and a 12 month high of $32.22.

Insider Buying and Selling at Avalyn Pharma

In other news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of Avalyn Pharma stock in a transaction on Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the acquisition, the insider owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jill Carroll acquired 277,778 shares of Avalyn Pharma stock in a transaction on Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the acquisition, the director owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This trade represents a 14.55% increase in their position. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.